Synthesis and characterization of αvβ₃-targeting peptidomimetic chelate conjugates for PET and SPECT imaging.
暂无分享,去创建一个
M. Brechbiel | D. Milenic | K. Baidoo | Young-Seung Kim | K. Nwe | S. Satz
[1] Oluwatayo F. Ikotun,et al. The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86. , 2011, Future medicinal chemistry.
[2] B. Pichler,et al. [68Ga]NODAGA-RGD for imaging αvβ3 integrin expression , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[3] C. Anderson,et al. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. , 2010, Chemical reviews.
[4] T. Quinn,et al. 203Pb-Labeled α-Melanocyte–Stimulating Hormone Peptide as an Imaging Probe for Melanoma Detection , 2008, Journal of Nuclear Medicine.
[5] J. Xie,et al. Radiolabeled high affinity peptidomimetic antagonist selectively targets αvβ3 receptor-positive tumor in mice , 2007 .
[6] M. Brechbiel,et al. In vitro and in vivo evaluation of novel ligands for radioimmunotherapy. , 2006, Nuclear medicine and biology.
[7] Zhimin Shen,et al. Synthesis, in vitro, and in vivo characterization of an integrin αvβ3-targeted molecular probe for optical imaging of tumor , 2005 .
[8] M. Brechbiel,et al. Purification of cyclotron-produced 203Pb for labeling Herceptin. , 2005, Nuclear medicine and biology.
[9] W. H. Knapp,et al. 68Ga-labelled DOTA-derivatised peptide ligands , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[10] Junichi Takagi,et al. Integrin activation and structural rearrangement , 2002, Immunological reviews.
[11] M. Bednarski,et al. Tumor Regression by Targeted Gene Delivery to the Neovasculature , 2002, Science.
[12] Sibylle Ziegler,et al. Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography , 2001 .
[13] M Schwaiger,et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] H. Mäcke,et al. A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labelling. , 2000, Bioorganic & medicinal chemistry letters.
[15] L. Chappell,et al. Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. , 2000, Nuclear medicine and biology.
[16] M. Brechbiel,et al. In vivo evaluation of a lead-labeled monoclonal antibody using the DOTA ligand , 1998, European Journal of Nuclear Medicine.
[17] M. Brechbiel,et al. Lead(II) complexes of 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetate: solution chemistry and application to tumor localization with 203Pb labeled monoclonal antibodies , 1995 .
[18] S. Mirzadeh,et al. The Chemical Fate of 212Bi-DOTA Formed by β- Decay of 212Pb(DOTA)2-*** , 1993 .
[19] S. Mirzadeh,et al. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. , 1990, Cancer research.
[20] Krishan Kumar,et al. Lead(II) and bismuth(III) complexes of the polyazacycloalkane-N-acetic acids nota, dota, and teta , 1989 .